Crossmark

Quality of life outcomes including neuropathy‐associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line chemotherapy for HER2‐negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13‐11)

Crossref DOI link: https://doi.org/10.1186/s40880-019-0375-7

Published Online: 2019-05-28

Published Print: 2019-12

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Kim, Ji‐Yeon

Park, Seri

Im, Seock‐Ah

Kim, Sung‐Bae

Sohn, Joohyuk

Lee, Keun Seok

Chae, Yee Soo

Lee, Ki Hyeong

Kim, Jee Hyun

Im, Young‐Hyuck

Kim, Tae‐Yong

Lee, Kyung‐Hun

Ahn, Jin‐Hee

Kim, Gun Min

Park, In Hae

Lee, Soo Jung

Han, Hye Sook

Kim, Se Hyun

Jung, Kyung Hae

Park, Yeon Hee

,
Funding

Funding for this research was provided by:

Eisai Korea
License Information

Version of Record valid from 2019-05-28
More Information

Publication History

Received: 2018-10-07

Accepted: 2019-05-16

Published: 2019-05-28

Document is current

Any future updates will be listed below